Shylendra B. Sreenivasappa
Expertise in
33
conditions

Dr. Shylendra B. Sreenivasappa

Hematology | Oncology
5666 East State Street, 
Rockford, IL 
Accepting New Patients
Offers Telehealth
Expertise in
33
conditions
5666 East State Street, 
Rockford, IL 

Overview

Shylendra Sreenivasappa is a Hematologist and an Oncologist practicing medicine in Rockford, Illinois.

Dr. Sreenivasappa is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Dr. Sreenivasappa is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, participating in 14 clinical trials. Dr. Sreenivasappa is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in IL

Board Certifications

American Board Of Internal Medicine

Fellowships

John H. Stroger, Jr. Hospital of Cook County, Hematology and Oncology, 2010

Hospital Affiliations

Osf Saint Elizabeth Mdl Ctr
Saint Anthony Medical Center
Osf Saint Paul Medical Center
Rochelle Community Hospital
Osf Saint Katharine Medical Center

Languages Spoken

English
Hindi
Kannada

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Pekin Life
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 11 Less Insurance Carriers -

Locations

OSF Saint Anthony - Cancer Center
5666 East State Street, Rockford, IL 61108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
15
conditions
Dr. Linda L. Ferris
Hematology | Oncology
Expertise in
15
conditions
Dr. Linda L. Ferris
Hematology | Oncology
Referral may be required
Before you request
10350 Haligus Rd Ste 120, 
Huntley, IL 
 (29.6 miles away)
312-695-1800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Linda Ferris is a Hematologist and an Oncologist practicing medicine in Huntley, Illinois. Dr. Ferris is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma. Dr. Ferris is currently accepting new patients.

Expertise in
29
conditions
Dr. Avanthi Ragam
Hematology | Oncology
Expertise in
29
conditions
Dr. Avanthi Ragam
Hematology | Oncology
Referral may be required
Before you request
304 Randall Rd, 
Geneva, IL 
 (43.2 miles away)
630-208-4060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Avanthi Ragam is a Hematologist and an Oncologist practicing medicine in Geneva, Illinois. Dr. Ragam is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Ragam is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Ragam is currently accepting new patients.

Expertise in
72
conditions
Dr. Stanley Nabrinsky
Hematology | Oncology
Expertise in
72
conditions
Dr. Stanley Nabrinsky
Hematology | Oncology
Referral may be required
Before you request

Illinois Cancer Specialists

1710 N Randall Rd, 
Elgin, IL 
 (36.8 miles away)
847-931-0909
Languages Spoken:
English, Russian, Ukrainian
See accepted insurances
Accepting New Patients
Offers Telehealth

Stanley Nabrinsky is a Hematologist and an Oncologist practicing medicine in Elgin, Illinois. Dr. Nabrinsky is highly rated in 72 conditions, according to our data. His clinical expertise encompasses Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Familial Colorectal Cancer. Dr. Nabrinsky is board certified in American Board Of Internal Medicine, Hematology. Dr. Nabrinsky is currently accepting new patients.

Frequently Asked Questions about Dr. Shylendra B. Sreenivasappa

How do I make an appointment with Dr. Shylendra B. Sreenivasappa?

You can book an appointment with Dr. Shylendra B. Sreenivasappa by calling their office at 815-227-2273. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shylendra B. Sreenivasappa a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shylendra B. Sreenivasappa is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shylendra B. Sreenivasappa specialize in?

While Dr. Shylendra B. Sreenivasappa is a Hematology, they have specific expertise in Colorectal Cancer, Lynch Syndrome, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Shylendra B. Sreenivasappa accept my insurance?

Dr. Shylendra B. Sreenivasappa accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 815-227-2273 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sreenivasappa's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 25 Advanced Conditions
    View All 121 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile